Federal Register / Vol. 75, No. 33 / Friday, February 19, 2010 / Notices 7489 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3218 Filed 2–18–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, 

Quantitative Imaging for Evaluation of 

Responses to Cancer Therapies. 

Date: March 4, 2010. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, Montgomery County 

Conference Center Facility, 5701 Marinelli 

Road, North Bethesda, MD 20852. 

Contact Person: Viatcheslav A 

Soldatenkov, M.D., PhD, Scientific Review 

Officer, Special Review and Logistics Branch, 

Division of Extramural Activities, National 

Cancer Institute, 6116 Executive Blvd., Room 

8057, Bethesda, MD 20892–8329. 301–451– 

4758. soldatenkovv@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR Topic 

258. 

Date: March 25, 2010. 

Time: 12:30 p.m. to 5:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Room 210, Rockville, 

MD 20852 (Telephone Conference Call). 

Contact Person: Viatcheslav A 

Soldatenkov, M.D., PhD, Scientific Review 

Officer, Special Review and Logistics Branch, 

Division of Extramural Activities, National 

Cancer Institute, 6116 Executive Blvd., Room 

8057, Bethesda, MD 20892–8329. 301–451– 

4758. soldatenkovv@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR Topic 

276. 

Date: March 26, 2010. 

Time: 12:30 p.m. to 5:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Room 210, Rockville, 

MD 20852 (Telephone Conference Call). 

Contact Person: Viatcheslav A 

Soldatenkov, M.D., PhD, Scientific Review 

Officer, Special Review and Logistics Branch, 

Division of Extramural Activities, National 

Cancer Institute, 6116 Executive Blvd., Room 

8057, Bethesda, MD 20892–8329. 301–451– 

4758. soldatenkovv@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Portable eTechnology Diet and Physical Activity Tools 

for Consumers. 

Date: April 7, 2010. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Room 405, Rockville, 

MD 20852 (Telephone Conference Call). 

Contact Person: Marvin L. Salin, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Boulevard, Room 7073, 

Bethesda, MD 20892–8329. 301–496–0694. 

msalin@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3189 Filed 2–18–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; The Early 

Detection Research Network: Clinical 

Validation Centers. 

Date: March 17, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Legacy Hotel and Meeting Center, 

1775 Rockville Pike, Rockville, MD 20852. 

Contact Person: Lalita D. Palekar, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, 6116 

Executive Boulevard, Room 7141, Bethesda, 

MD 20892, 301–496–7575, 

palekarl@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI Cancer 

Nanotechnology Training (R25) and Career 

Development Award (K99/R00) Applications. 

Date: March 23–24, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Jeannette F Korczak, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Blvd., Room 

8115, Bethesda, MD 20892, 301–496–9767, 

korczakj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3191 Filed 2–18–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 


pwalker on DSK8KYBLC1PROD with NOTICES
7490 Federal Register / Vol. 75, No. 33 / Friday, February 19, 2010 / Notices 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 74 FR 68630–3 1, dated 

December 28, 2009) is amended to 

reflect the establishment of the Office of 

Noncommunicable Diseases, Injury and 

Environmental Health. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

After the mission statement for the 

Centers for Disease Control and 

Prevention (C), delete the title and insert 

the following: 

Office of Noncommunicable Diseases, 

Injury and Environmental Health (CU). 

The mission of the Office of 

Noncommunicable Diseases, Injury and 

Environmental Health (ONDIEH) is to 

reduce the burden of noncommunicable 

diseases, injuries, disabilities and 

environmental health hazards. 

Office of the Director (CUA). (1) 

Advises the CDC Director on issues 

related to noncommunicable diseases, 

injury prevention, disability, and 

environmental health; (2) provides 

overall strategic direction and 

leadership for noncommunicable 

diseases, injury prevention, disability 

and environmental health; (3) promotes 

and supports noncommunicable 

diseases, injury prevention, disability, 

and environmental health related 

science, policies and programs; and (4) 

identifies, facilitates, and promotes 

cross center and cross-agency 

collaboration, innovation, and new 

initiatives related to noncommunicable 

diseases, injury prevention, disability, 

and environmental health. 

Dated: February 3, 2010. 

William P. Nichols, 

Acting Chief Operating Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2010–3069 Filed 2–18–10; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0376] 

Office of the Commissioner 

Reorganization; Statement of 

Organizations, Functions, and 

Delegations of Authority 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

reorganization of the Office of the 

Commissioner (OC). This reorganization 

includes the organizations and their 

substructure components as listed in 

this document. This notice was 

previously published in the Federal 

Register of August 18, 2009, but it 

contained several errors. For the 

convenience of the reader, the 

reorganization is being published again 

in its entirety. 

FOR FURTHER INFORMATION CONTACT: 

Vanessa Starks, Office of Management 

Programs (HFA–400), Food and Drug 

Administration, 5600 Fishers Lane, rm. 

6B–42, Rockville, MD 20857, 301–827– 

1463. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of August 18, 2009 (74 

FR 41713), FDA published a notice 

announcing the reorganization of the 

Office of the Commissioner (OC). This 

reorganization includes the realignment 

of four Deputy-level offices within OC. 

They are as follows: (1) The Office of the 

Chief Scientist; (2) the Office of 

Administration (formerly titled the 

Office of Operations); (3) the Office of 

Foods; and (4) the Office of Policy, 

Planning and Budget (formerly titled the 

Office of Policy, Planning and 

Preparedness). 

Office of Chief of Staff: The Office of 

Chief of Staff will advise and provide 

integrated policy analysis and strategic 

consultation to the Commissioner, the 

Principal Deputy Commissioner, Deputy 

Commissioners, and other senior FDA 

officials on activities and issues that 

affect significant agency programs, 

projects and initiatives. Often this 

function involves the most difficult 

problems, crisis situations and 

extremely complex issues of the 

Agency. This Office will include the 

Executive Secretariat Staff. This Office 

will report directly to the 

Commissioner. 

Office of Legislation: The Office of 

Legislation will be restructured from the 

Office of the Chief of Staff. The Office 

of Legislation will report directly to the 

Commissioner and have an indirect 

reporting relationship to the Deputy 

Commissioner for Policy, Planning and 

Budget. 

Office of Policy, Planning and Budget: 

The Office of Policy, Planning and 

Budget will be retitled from the Office 

of Policy, Planning and Preparedness. 

The Office of Policy, Planning and 

Budget will be restructured to consist of 

the Office of Policy, the Office of 

Planning and the Office of Budget 

(formerly the Office of Budget 

Formulation and Presentation). The 

Office of Policy will consist of the 

Policy Development and Coordination 

Staff, Regulations Policy and 

Management Staff, and Regulations 

Editorial Section. The Office of Planning 

will consist of the Planning Staff, 

Evaluation Staff, Economic Staff, Risk 

Communication Staff, and Business 

Process Planning Staff. The Office of 

Policy, Planning and Budget will report 

directly to the Commissioner. 

Office of the Counselor to the 

Commissioner: The Office of the 

Counselor to the Commissioner will be 

established to formulate and render 

advice to the Commissioner that is 

related to policy development, 

interpretation, and integration that cuts 

across program lines or which is not 

well defined. This Office will include 

the Office of Crisis Management. The 

Office of the Counselor to the 

Commissioner will report directly to the 

Commissioner. 

Office of Women’s Health: The Office 

of Women’s Health will be realigned 

from the Office of the Chief Scientist, 

Office of Science and Health 

Coordination. The Office of Women’s 

Health will report directly to the 

Commissioner. 

Office of Special Medical Programs: 

The Office of Special Medical Programs 

is a newly created Office within OC 

with functions and substructure 

realigned from components of existing 

offices. The Office of Special Medical 

Programs will consist of the following 

components: Office of Pediatric 

Therapeutics, Office of Combination 

Products, Office of Orphan Product 

Development, and Office of Good 

Clinical Practice (formerly titled the 

Good Clinical Practice Program) which 

all will be realigned from the Office of 

the Chief Scientist. The Office of Special 

Medical Programs will also include the 

Advisory Committee Management and 

Oversight Staff (formerly in the Office of 

Policy, Planning, and Preparedness). 

This Office will report directly to the 

Commissioner. 

Office of External Affairs: The Office 

of External Affairs will be established to 

serve as a focal point for improving 

FDA’s communications to media, 

Congress, and the general public; and to 

also advise the Commissioner on better 

internal communications within the 

Agency. This Office will consist of the 

Office of External Relations, the Office 

of Public Affairs and the Office of 

Special Health Issues. This Office will 

report directly to the Commissioner. 

Office of Foods: The Office of Foods 

will be established to elevate and 

empower our food safety activities. This 

office, led by the Deputy Commissioner 

for Foods, will provide executive 

leadership and management to all FDA 

food programs, and will be accountable 


pwalker on DSK8KYBLC1PROD with NOTICES